Pneumococcal conjugate vaccine use in adults

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination

(2015) As’ad E. Bhorat et al.   AIDS

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study

(2015) Catherine Cordonnier et al.   CLINICAL INFECTIOUS DISEASES

Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence

(2015) Daniel Curcio et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

(2015) Pauline A Waight et al.   LANCET INFECTIOUS DISEASES

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

(2015) Marc J.M. Bonten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: Table 1

(2015) Antoni Torres et al.   THORAX

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18–49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine

(2015) K.A. Bryant et al.   VACCINE

Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

(2015) Miwako Kobayashi et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Open-Label Trial of Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Adults ≥50 Years of Age in Mexico

(2014) Juan Carlos Tinoco et al.   Clinical and Vaccine Immunology

Early Impact of 13-Valent Pneumococcal Conjugate Vaccine on Community-Acquired Pneumonia in Children

(2014) F. Angoulvant et al.   CLINICAL INFECTIOUS DISEASES

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine

(2014) M. J. Glesby et al.   JOURNAL OF INFECTIOUS DISEASES

Changes in Childhood Pneumonia and Infant Mortality Rates Following Introduction of the 13-valent Pneumococcal Conjugate Vaccine in Nicaragua

(2014) Sylvia Becker-Dreps et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Sinusitis and Pneumonia Hospitalization After Introduction of Pneumococcal Conjugate Vaccine

(2014) Ann Lindstrand et al.   PEDIATRICS

All-Cause Pneumonia Hospitalizations in Children

(2014) Anders Berglund et al.   PLoS One

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

(2014) Richard N. Greenberg et al.   VACCINE

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies

(2014) Emanuele Amodio et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years

(2014) Masanari Shiramoto et al.   Human Vaccines & Immunotherapeutics

Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis

(2014) Lone Simonsen et al.   Lancet Respiratory Medicine

Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions

(2014) Kimberly M. Shea et al.   Open Forum Infectious Diseases

Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial

(2013) Ron Dagan et al.   CLINICAL INFECTIOUS DISEASES

Pneumococcal infection in adults: burden of disease

(2013) J.J.C. Drijkoningen et al.   CLINICAL MICROBIOLOGY AND INFECTION

Distribution of 13-Valent Pneumococcal Conjugate Vaccine Streptococcus pneumoniae Serotypes in US Adults Aged >=50 Years With Community-Acquired Pneumonia

(2013) R. L. Sherwin et al.   JOURNAL OF INFECTIOUS DISEASES

Acute pneumonia and the cardiovascular system

(2013) Vicente F Corrales-Medina et al.   LANCET

Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine

(2013) Sheldon L. Kaplan et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques

(2013) Maria A. Said et al.   PLoS One

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

(2013) Lisa A. Jackson et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

(2013) Lisa A. Jackson et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

(2013) Lisa A. Jackson et al.   VACCINE

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

(2013) Anneke Steens et al.   VACCINE

Serotype-independent pneumococcal vaccines

(2012) Eliane Namie Miyaji et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Incidence and Cost of Pneumonia in Medicare Beneficiaries

(2012) Cindy Parks Thomas et al.   CHEST

Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine

(2012) Michael W. Pride et al.   Clinical and Vaccine Immunology

Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults

(2012) Robert W. Frenck et al.   Clinical and Vaccine Immunology

Pneumococcal Conjugate Vaccine for Adults: A New Paradigm

(2012) P. R. Paradiso   CLINICAL INFECTIOUS DISEASES

Understanding the burden of pneumococcal disease in adults

(2012) F. Blasi et al.   CLINICAL MICROBIOLOGY AND INFECTION

Experiencing Simulated Aging Improves Knowledge of and Attitudes Toward Aging

(2012) Chiu-Yen Yu et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Impact of 13-valent Pneumococcal Conjugate Vaccine on Pneumococcal Nasopharyngeal Carriage in Children With Acute Otitis Media

(2012) Robert Cohen et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia

(2012) Thomas Bewick et al.   THORAX

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales

(2012) Nick J. Andrews et al.   VACCINE

Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years

(2012) Tino F. Schwarz et al.   VACCINE

Healthcare utilization and cost of pneumococcal disease in the United States

(2011) Susan S. Huang et al.   VACCINE

A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years

(2011) T.F. Schwarz et al.   VACCINE

Impact of Pneumococcal Conjugate Vaccination of Infants on Pneumonia and Influenza Hospitalization and Mortality in All Age Groups in the United States

(2011) L. Simonsen et al.   mBio

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults

(2010) Neil French et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and economic burden of pneumococcal disease in older US adults

(2010) Derek Weycker et al.   VACCINE

Efficacy of pneumococcal vaccination in adults: a meta-analysis

(2009) A. Huss et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Severity of Pneumococcal Pneumonia Associated With Genomic Bacterial Load

(2009) Jordi Rello et al.   CHEST

Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

(2008) Jennifer C. Nelson et al.   VACCINE